ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 6, 2021

8:30AM-10:30AM: Abstract Number: 0162

Cardiac Magnetic Resonance Imaging for Guiding Decision-making on Treatment Duration: Data from RHAPSODY, a Phase 3 Clinical Trial of Rilonacept in Recurrent Pericarditis

Imaging of Rheumatic Diseases Poster (0149–0182)

8:30AM-10:30AM: Abstract Number: 0083

Cardiac Valve Surgery Outcomes in the Antiphospholipid Syndrome

Antiphospholipid Syndrome Poster (0069–0083)

8:30AM-10:30AM: Abstract Number: 0286

Cardiovascular Disease Risk in Inflammatory Arthritis Patients Still Substantially Elevated in 2020

RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)

8:30AM-10:30AM: Abstract Number: 0283

Cardiovascular Risk Management in Patients with Rheumatoid Arthritis: A Single-centered Cross-sectional Study

RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)

8:30AM-10:30AM: Abstract Number: 0018

Caspase-8 Variant G Regulates Rheumatoid Arthritis Fibroblast-Like Synoviocyte Aggressive Behavior

RA – Etiology & Pathogenesis Poster (0011–0045)

8:30AM-10:30AM: Abstract Number: 0429

Causes and Characteristics of Death in ANCA-Associated Vasculitis – A Large, Real-Life, Contemporary Cohort Analysis

Vasculitis – ANCA-Associated Poster (0414–0436)

8:30AM-10:30AM: Abstract Number: 0049

CC-99677, a Novel, Selective, Oral MK2 Inhibitor, Sustainably Reduces Pro-inflammatory Cytokine Production and Ameliorates Inflammation in the Mannan-Induced Murine Model of Psoriasis and Psoriatic Arthritis

Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)

8:30AM-10:30AM: Abstract Number: 0307

Cerebellar Ataxia in Primary Sjogren’s Syndrome, Is Gluten Sensitivity the Answer?

Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)

8:30AM-10:30AM: Abstract Number: 0133

Cervical Cancer Screening Rate in Women with Systemic Lupus Erythematosus

Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)

8:30AM-10:30AM: Abstract Number: 0094

Characteristics Associated with Severe Outcomes in Patients with Systemic Rheumatic Diseases Hospitalized for COVID-19 in New York City

Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)

8:30AM-10:30AM: Abstract Number: 0066

Characterization of αβTCR of HLA-B*27-Restricted CD8 T-Cell Clones Associated with Spondyloarthropathies

Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)

8:30AM-10:30AM: Abstract Number: 0203

Chemoprophylaxis in Latent Tuberculosis Associated with Rheumatic Immune-mediated Diseases. Study of 240 Patients from a Single University Hospital

Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)

8:30AM-10:30AM: Abstract Number: 0020

Citrullination Drives the Expression of Pro-fibrotic Genes in Rheumatoid Arthritis Fibroblast-like Cells

RA – Etiology & Pathogenesis Poster (0011–0045)

8:30AM-10:30AM: Abstract Number: 0130

Clinical and Economic Characterization of Systemic Lupus Erythematosus Patients: Real World Observation Across Disease Severity and Payer Channels in the U.S

Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)

8:30AM-10:30AM: Abstract Number: 0431

Clinical Characteristics and Outcomes of ANCA-Associated and Non Immune-Mediated Hypertrophic Pachymeningitis: A Comparative Study

Vasculitis – ANCA-Associated Poster (0414–0436)

«Previous Page
1
…
3
4
5
6
7
…
34
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].